Physician profile
Mark C Glaum
NPI 1073598744
$336,550.80
in general payments reported to CMS, 2019-2025
28 companies · $109K in 2025
The $109K reported for 2025 was more than what 98% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $20K · 2021: $29K · 2022: $43K · 2023: $13K · 2024: $44K · 2025: $109K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $129K · Travel and Lodging: $19K · Consulting Fee: $13K · Food and Beverage: $5,086 · Education: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $129,292.75 |
| Travel and Lodging | $18,591.99 |
| Consulting Fee | $12,841.16 |
| Food and Beverage | $5,085.66 |
| Education | $509.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $91,281.27 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Shire North American Group INC | $76,880.11 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74,219.67 | 2020-2025 | Takhzyro, Cinryze, Cuvitru |
| Biocryst US Sales Co., LLC | $65,274.38 | 2021-2025 | Orladeyo |
| Ionis Pharmaceuticals, INC. | $18,232.10 | 2025 | Dawnzera |
| Biocryst Pharmaceuticals, INC. | $3,429.79 | 2020-2024 | |
| Genentech USA, INC. | $1,766.96 | 2019-2022 | |
| Alk-Abello, INC | $1,609.21 | 2021 | |
| Blueprint Medicines Corporation | $1,485.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $480.67 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $451.00 | 2019-2024 | Dupixent |
| Glaxosmithkline, LLC. | $304.47 | 2019-2025 | Nucala, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $190.98 | 2022-2023 | |
| Pfizer INC. | $188.12 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $159.00 | 2019-2025 | Fasenra, Airsupra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $147.78 | 2019-2025 | |
| Amgen INC. | $67.95 | 2025 | Tezspire |
| Pharming Healthcare, INC. | $65.32 | 2019-2025 | Ruconest |
| Covis Pharma Gmbh | $58.94 | 2019-2022 | |
| Leo Pharma INC. | $50.42 | 2023-2024 | Adbry |
| Optinose US, INC. | $45.06 | 2022-2023 | |
| Kaleo, INC. | $43.25 | 2019-2023 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $29.25 | 2025 | Neffy |
| Grifols USA, LLC | $21.09 | 2024 | Xembify |
| Galderma Laboratories, L.P. | $20.53 | 2025 | Nemluvio |
| Hikma Pharmaceuticals USA | $18.86 | 2025 | Ryaltris |
| Abbvie INC. | $18.19 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Glaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.